KK
PTGX icon

KLP Kapitalforvaltning’s Protagonist Therapeutics PTGX Stock Holding History

KLP Kapitalforvaltning’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
11,600
+600
+5% +$62.7K ﹤0.01% 946
2026
Q1 		$1.16M Buy
11,000
+400
+4% +$35.4K ﹤0.01% 951
2025
Q4 		$926K Buy
10,600
+200
+2% +$16.4K ﹤0.01% 1073
2025
Q3 		$691K Hold
10,400
– – ﹤0.01% 1241
2025
Q2 		$575K Buy
10,400
+1,700
+20% +$81.6K ﹤0.01% 1292
2025
Q1 		$421K Hold
8,700
– – ﹤0.01% 1392
2024
Q4 		$336K Buy
+8,700
New +$379K ﹤0.01% 1587

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

KLP Kapitalforvaltning's PTGX Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Protagonist Therapeutics (PTGX) stake by 5.5% in Q2 2026, buying an estimated $62.7K and bringing the position to 11,600 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #946.

KLP Kapitalforvaltning first reported a position in PTGX in Q4 2024 and has held it in 7 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • KLP Kapitalforvaltning held 11,600 shares of Protagonist Therapeutics worth $1.42M as of Q2 2026.
  • KLP Kapitalforvaltning bought 600 Protagonist Therapeutics shares in Q2 2026, an estimated $62.7K.
  • Protagonist Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #946 holding.
  • KLP Kapitalforvaltning first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.